22 Jan, 2019 11:14 AM
Mirax Corporation appointed as exclusive distributor for Korea
Important expansion of commercial opportunity in high-growth Asian IVD market
Melbourne, Australia, 22 January 2019: Sienna Cance...read more
14 Jan, 2019 09:49 AM
Lu-PIN-1 Study two-thirds enrolled
Study testing ability of Veyonda to boost effect of Novartis experimental drug
Noxopharm to initiate LuPIN-2 study.
SYDNEY, January 14, 2019: Noxopharm (...read more
08 Jan, 2019 03:07 AM
- President of City of Hope National Medical Center and holds the Deana and Steve Campbell Physician-in-Chief.
- Elected President of the American Association for Cancer Research (AACR) in 2017, th...read more
21 Dec, 2018 08:53 AM
Sydney, Australia - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (“Immutep“ or “the Company“) On 19 December 2018, the Company announced that it had entered into a securities purchas...read more
21 Dec, 2018 08:52 AM
With respect to the shares the subject of this issuance as detailed in the Appendix 3B lodged today, the Company gives notice under section 708A(5)(e) of the Corporations Act 2001(Cth) (the "Corp...read more
20 Dec, 2018 08:14 AM
For the issue by the Company of 2,080,000 Warrants convertible into 208,000,000 Warrant Shares (in aggregate) at an exercise price of US$0.025 per Warrant Share.
This Prospectus has been prepared f...read more
19 Dec, 2018 03:10 PM
Extends the Company’s cash runway into mid-2020, during which time Immutep is expected to report meaningful clinical data
SYDNEY, AUSTRALIA – December 19, 2018 – Immutep Limited ...read more
17 Dec, 2018 10:00 AM
Safety, tolerability & phase 2 dose determined
Phase 2 trial first patient to be dosed early 2019
5 patients with partial responses
4 patients with stable disease
SYDNEY, Australia...read more
11 Dec, 2018 08:52 AM
Trial to enrol final 12 patients at 1200mg dose
Based on positive safety and clinical response data
Next scheduled review late-January 2019
SYDNEY, December 11, 2018: Noxopharm (ASX:NOX) a...read more
